All In Biotech

BLA 019938 · Novo Nordisk INC

Novolin R

Insulin Recombinant Human · Injection · Insulin

Last checked: Nov 20, 2026Latest source record: Nov 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Jun 25, 1991

Approved uses

2

Original approval plus efficacy supplements

Registered trials

100

15 Phase 3, 0 recruiting

FAERS reports

7,159

5,139 serious, 819 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 23, 2022.

NOVOLIN R is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. NOVOLIN R is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus ( 1 ).

Mechanism: The primary activity of insulin, including NOVOLIN R is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 21, 2005 Supplement 48 · Efficacy Label
  • Jun 25, 1991 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • NOVOLIN R · INSULIN RECOMBINANT HUMAN 100 UNITS/ML · INJECTABLE, INJECTION · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Recombinant Human" as an intervention, any sponsor and status, largest first.

All 100 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased1,019
  • drug ineffective378
  • nausea376
  • blood glucose decreased361
  • hypoglycaemia298
  • diarrhoea294
  • dyspnoea276
  • renal failure249
  • fatigue239
  • dizziness236
  • fall233
  • death227

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200487
2005162
2006212
2007131
2008201
2009337
2010255
2011212
2012249
2013290
2014357
2015811
2016553
2017549
2018635
2019562
2020297
2021294
2022219
2023167
2024195
2025276
2026108

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Novolin R (Insulin Regular, Human)

2024 spending

$10.6M

Beneficiaries

30,617

106,120 claims

Per beneficiary

$347

$4.64 per unit

View as table
YearSpending
2020$54,534,741
2021$48,224,402
2022$42,548,490
2023$37,170,815
2024$10,628,012

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.